Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Marina Zajec, Pieter Langerhorst, Somayya Noori, Martijn van Duijn, Yolanda de Rijke, Jolein Gloerich, Alain van Gool, Jill Corre, PharmD, PhD, Thomas Dejoie, Helene Caillon, Joannes Jacobs, Theo Luider, Herve Avet-Loiseau

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-139330

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Titouan Cazaubiel, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Romain Lannes, PhD, Aurore Perrot, Cyrille Hulin, MD, Hervé Avet-Loiseau, MD PhD, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139340

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139066

Published: 2020

Journal Articles

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Anaïs Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Herve Avet-Loiseau, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136996

Published: 2020

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Hervé Avet-Loiseau, MD PhD, Valerie Lauwers-Cances, MD, Jill Corre, PharmD, PhD, Philippe Moreau, MDPhD, Michel Attal, MD PhD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 435.

https://doi.org/10.1182/blood.V130.Suppl_1.435.435

Published: 2017

Journal Articles

Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy

Camille Claracq, PharmD, Murielle Roussel, MD, Benjamin Hébraud, MD, Michel Attal, MD, Herve Avet Loiseau, MD PhD, Jill Corre, PharmD, PhD

Blood (2014) 124 (21): 3396.

https://doi.org/10.1182/blood.V124.21.3396.3396

Published: 2014

Journal Articles

in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Jill Corre, PharmD, PhD, Benjamin Hebraud, MD, Florence Magrangeas, PhD, Valérie Lauwers-Cances, MD, Marie-Lorraine Chretien, MD, Stephane Minvielle, PhD, Hervé Avet-Loiseau

Blood (2014) 124 (21): 641.

https://doi.org/10.1182/blood.V124.21.641.641

Published: 2014

Journal Articles

Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Jill Corre, PharmD, PhD, Thomas Dejoie, PharmD, Helene Caillon, PharmD, Michel Attal, MD, Herve Avet-Loiseau, Philippe Moreau, MD

Blood (2014) 124 (21): 180.

https://doi.org/10.1182/blood.V124.21.180.180

Published: 2014

Journal Articles

Characterization of Mesenchymal Stem Cells Abnormalities in Multiple Myeloma.

Philippe Bourin, MD, PhD, Jill Corre, PharmD, Karène Mahtouk, PhD, Mélanie Gadelorge, Ing, Patrick Laharrague, MD, PhD, Bernard Klein, PhD, Thierry Rème, MD, PhD, Michel Attal, MD, PhD

Blood (2006) 108 (11): 511.

https://doi.org/10.1182/blood.V108.11.511.511

Published: 2006

NARROW

Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy

in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Characterization of Mesenchymal Stem Cells Abnormalities in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only